Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.41M
Average 1.73M
LRMR Operating Cash Flow
Cash generated by the company's core business operations during the period.
Larimar Therapeutics, Inc.NASDAQ: LRMR
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $44.61M (cash outflow) rose 68.1% year over year, ahead of the +51.1% change in trailing-twelve-month operating cash flow. Sequentially, it rose 15.8% from the prior quarter. Over 3 fiscal years it compounded at +60.1% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +68.1% holds above the trailing-twelve-month pace of +51.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (113.2M) USD
- Year-over-year change
- -60.0%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (113.2M) | -60.0% |
| FY2024 | 2024-12-31 | (70.76M) | -111.5% |
| FY2023 | 2023-12-31 | (33.46M) | -21.4% |
| FY2022 | 2022-12-31 | (27.57M) | +34.5% |
| FY2021 | 2021-12-31 | (42.11M) | — |
Operating Cash Flow vs competitors
How LRMR compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +51.1% is the 3rd highest of 11, against a peer median of +15.0%.
- Over three fiscal years its annual growth of +60.1% compares with a peer median of +21.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $183.1M USD | +31.0% | +17.0% | — | |
| LTM Mar 2026 | $150.61M USD | +68.4% | +29.6% | — | |
| LTM Mar 2026 | $150.39M USD | +12.5% | +62.1% | — | |
| LTM Mar 2026 | $131.28M USD | +51.1% | +60.1% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $110M USD | +45.9% | +78.0% | — |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $97.99M USD | +11.4% | +21.8% | — |
| LTM Mar 2026 | $71.94M USD | -10.5% | +2.6% | 199819.4% | |
| LTM Mar 2026 | $70.18M USD | +12.1% | +13.6% | 1826.7% | |
| LTM Dec 2025 | CHF 69.2M CHF | -205.1% | -3.5% | 1936.8% | |
| LTM Mar 2026 | $62.3M USD | +17.6% | +36.4% | — | |
| LTM Mar 2026 | $25.51M USD | +182.6% | — | 11.9% | |
| Peer median (excluding LRMR) | — | +15.0% | +21.8% | 1881.8% | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Depreciation & Amortization | 326K | 318K | 311K | 318K | (1.35M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.47M | 6.62M | 7.62M | 8.8M | 7M |
| Change in Working Capital | 2.75M | 1.67M | (2.51M) | 6.18M | 47.1M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (974K) | 26K | (403K) | 1.14M | 2.79M |
| Other Working Capital | 3.72M | 1.64M | (2.11M) | 5.03M | 44.31M |
| Other Non-Cash Items | (15K) | (820K) | (1.93M) | (5.45M) | (281K) |
| Operating Cash Flow | (42.11M) | (27.57M) | (33.46M) | (70.76M) | (113.2M) |
| Capital Expenditures | (333K) | (100K) | (164K) | (515K) | (91K) |
| Acquisitions (Net) | (24.5K) | 90.86K | 0 | 0 | 0 |
| Purchases of Investments | (8.25M) | (133.61M) | (101.23M) | (227.87M) | (83.6M) |
| Sales of Investments | 32.75M | 42.75M | 134.75M | 143M | 184M |
| Other Investing Activities | 24.5K | (90.86K) | 0 | 0 | 0 |
| Investing Cash Flow | 24.17M | (90.96M) | 33.35M | (85.39M) | 100.31M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 19.89M | 75.26M | 30K | 161.81M | 65.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 77K | 0 |
| Financing Cash Flow | 19.89M | 75.26M | 30K | 161.88M | 65.09M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.95M | (43.27M) | (76K) | 5.74M | 52.19M |
| Free Cash Flow | (42.44M) | (27.67M) | (33.62M) | (71.28M) | (113.29M) |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$3.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.